2022
DOI: 10.1016/j.jfma.2022.02.020
|View full text |Cite
|
Sign up to set email alerts
|

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
20
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 23 publications
(22 citation statements)
references
References 16 publications
2
20
0
Order By: Relevance
“…Our findings were consistent with studies performed on the healthy population, where lower humoral response was reported in inactivated vaccine when compared to adenovirus-vectored or mRNA vaccine [17,18]. The other studies also found that heterologous adenovirus-vectored/mRNA vaccination was more immunogenic than homologous adenovirus-vectored vaccination [19,20]. Vaccine type remains to be a strong independent predictor of humoral immune response in AIRD patients, even when it is adjusted for other potential confounders, including baseline characteristics and immunosuppressive load.…”
Section: Discussionsupporting
confidence: 92%
“…Our findings were consistent with studies performed on the healthy population, where lower humoral response was reported in inactivated vaccine when compared to adenovirus-vectored or mRNA vaccine [17,18]. The other studies also found that heterologous adenovirus-vectored/mRNA vaccination was more immunogenic than homologous adenovirus-vectored vaccination [19,20]. Vaccine type remains to be a strong independent predictor of humoral immune response in AIRD patients, even when it is adjusted for other potential confounders, including baseline characteristics and immunosuppressive load.…”
Section: Discussionsupporting
confidence: 92%
“…Our findings were consistent with studies performed on healthy population where lower humoral response was reported in inactivated vaccine when compared to adenovirus-vectored or mRNA vaccine (17, 18). Heterologous adenovirus-vectored /mRNA vaccination was also more immunogenic than homologous adenovirus-vectored vaccination and comparable to homologous mRNA vaccination (19, 20). Vaccine type remains to be a strong independent predictor of humoral immune response in AIRD patients, even adjusted for other potential confounders including baseline characteristics and immunosuppressive load.…”
Section: Discussionmentioning
confidence: 94%
“…We have previously addressed the immune responses and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination with prime-boost intervals of 4 and 8 weeks, compared with homologous ChAdOx1 vaccination and homologous mRNA-1273 vaccination separately. 10 The SARS-CoV-2 anti-spike IgG titers and neutralization antibody titers against SARS-CoV-2 variants, as well as T-cell responses to heterologous vaccinations with either 4- or 8-week intervals, were significantly higher than that of homologous ChAdOx1 vaccination and comparable to homologous mRNA-1273 vaccination. Heterologous prime-boost ChAdOx1/mRNA-1273 vaccination with an 8-week interval had significantly higher mean neutralizing antibody titers than the 4-week interval of heterologous ChAdOx1/mRNA-1273 vaccination at day 28 after the booster dose.…”
Section: Introductionmentioning
confidence: 89%
“…Enrollment criteria and test schedules were the same as those of our previous study. 10 The serum SARS-CoV-2 anti-spike IgG titers and neutralizing antibody titers were determined as described in our previous report. 10 The primary outcome was the analysis of serum SARS-CoV-2 anti-spike IgG titers and neutralizing antibody titers against B.1.1.7 (alpha) and the B.1.617.2 (delta) SARS-CoV-2 variants at day 28 after the booster.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation